Evidence map›Paper›PMID 38730089›Full record

Observational studyWorld journal of urology2024

Urosepsis 30-day mortality, morbidity, and their risk factors: SERPENS study, a prospective, observational multi-center study.

Zafer Tandogdu, Bela Koves, Slobodan Ristovski, Mustafa Bahadir Can Balci, Kristin Rennesund, Stavros Gravas, DjordJe Nale, José Medina-Polo, Mária Kopilec Garabášová, Elisabetta Costantini and 9 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02380170 (Epidemiology and Outcomes of Gram Negative Urosepsis), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02380170 completednot on this map

Epidemiology and Outcomes of Gram Negative Urosepsis

TypeobservationalSponsorEuropean Association of Urology Research FoundationRan2014 to 2020Enrolled600ConditionsUrosepsis
3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. CAUTIon - not all UTIs are the same.Nature reviews. Urology · 2025
    Review
  13. Article
  14. Article
  15. Is GDF15 a Feasible Biomarker in Sepsis?Diagnostics (Basel, Switzerland) · 2025
    Article
  16. Antibiotic practices in kidney transplant recipients with urosepsis are associated with treatment outcomes - a post-hoc analysis of an observational study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Observational
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Zafer TandogduUniversity College London Hospitals, London, UK. drzafer@gmail.com.ORCID http://orcid.org/0000-0002-5309-3656
Bela KovesSouth Pest Teaching Hospital, Budapest, Hungary.
Slobodan RistovskiUniversity Clinic for Surgical Diseases "St. Naum Ohridski" Skopje, Skopje, Republic of North Macedonia.
Mustafa Bahadir Can BalciGaziosmanpasa Taksim Teaching Hospital, Istanbul, Turkey.
Kristin RennesundUrology Department, Oslo University Hospital, Oslo, Norway.
Stavros GravasUniversity Hospital of Larissa, Larissa, Greece.
DjordJe NaleClinic of Urology, University Clinical Center of Serbia, Faculty of Medicine, Belgrade, Serbia.
José Medina-PoloHospital Universitario, 12 de Octubre imas12, Madrid, Spain.
Mária Kopilec GarabášováTeaching Hospital Trenčín, Trenčín, Slovakia.
Elisabetta CostantiniOspedale Santa Maria della Misericordia di Perugia, Perigia, Italy.
Jorge Cano-ValascoHospital General Universitario Gregorio Marañón, Madrid, Spain.
Maja Sofronievska GlavinovaSurgical Clinic St. Naum Ohridski, Skopje, Republic of North Macedonia.
Franck BruyereUrology, CHRU Bretonneau, Tours, France.
Tamara PerepanovaS.R. Institute of Urology, Moscow, Russian Federation.
Ekaterina KulchavenyaNovosibirsk Research Institute of Tuberculosis, Novosibirsk, Russian Federation.
Mete CekDepartment of Urology, Trakya University Medical School, Edirne, Turkey.
Florian Wagenlehner *Justus Liebig University, Giessen, Germany.
Truls Erik Bjerklund Johansen *University of Oslo, Oslo, Norway.
SERPENS Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo provide a descriptive report of mortality and morbidity in the first 30 days of diagnosis of urosepsis. Secondary aim is to identify risk factors of unfavourable outcomes.

methodsProspective observational multicentre cohort study conducted from September 2014 to November 2018 in European hospitals. Adult patients (≥ 18 years) diagnosed with acute urosepsis according to Sepsis-2 criteria with confirmed microbiological infection were included. Outcomes were classified in one of four health states: death, multiple organ failure, single organ failure, and recovery at day 30 from onset of urosepsis. Descriptive statistics and ordinal logistic regression analysis was performed.

resultsThree hundred and fifty four patients were recruited, and 30-day mortality rate was 2.8%, rising to 4.6% for severe sepsis. All patients who died had a SOFA score of ≥ 2 at diagnosis. Upon initial diagnosis, 79% (n = 281) of patients presented with OF. Within 30 days, an additional 5% developed OF, resulting in a total of 84% affected. Charlson score (OR 1.14 CI 1.01-1.28), patients with respiratory failure at baseline (OR 2.35, CI 1.32-4.21), ICU admission within the past 12 months (OR 2.05, CI 1.00-4.19), obstruction causative of urosepsis (OR 1.76, CI 1.02-3.05), urosepsis with multi-drug-resistant(MDR) pathogens (OR 2.01, CI 1.15-3.53), and SOFA baseline score ≥ 2 (OR 2.74, CI 1.49-5.07) are significantly associated with day 30 outcomes (OF and death).

conclusionsImpact of comorbidities and MDR pathogens on outcomes highlights the existence of a distinct group of patients who are prone to mortality and morbidity. These findings underscore the need for the development of pragmatic classifications to better assess the severity of UTIs and guide management strategies. STUDY REGISTRATION: Clinicaltrials.gov registration number NCT02380170.

Indexed as

SepsisUrinary Tract InfectionsAgedAged, 80 and overCohort StudiesFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsTime FactorsAntibiotic resistanceSevere UTIUrosepsis

Identifiers

PMID38730089
PMCPMC11087335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.